Natural products and the search for novel vaccine adjuvants

Vaccine

Volumn 29, Issue 38, 2011, Pages 6464-6471

  Rey Ladino, Jose ^a   Ross, Allen G ^a   Cripps, Allan W ^a   McManus, Donald P ^b   Quinn, Ronald ^c  

^a GRIFFITH UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Adjuvants; Dendritic cells; Immune activating compounds; Natural products; Pathogen associated molecular patterns; Pattern recognition receptors

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ASTRAGALUS MEMBRANACEUS EXTRACT; BETA GLUCAN; CD209 ANTIGEN; DECTIN 1; DOUBLE STRANDED RNA; FLAGELLIN; GINSENG EXTRACT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 27; LANGERIN; LECTIN RECEPTOR; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; NATURAL PRODUCT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PEPTIDOGLYCAN; QS 21; RETINOIC ACID INDUCIBLE GENE LIKE RECEPTOR; RETINOIC ACID RECEPTOR; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN PRESENTATION; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG RECEPTOR BINDING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; BIOLOGICAL AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; VACCINES;

EID: 80051672264     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.041     Document Type: Review

References (121)

1. Kwissa M., Kasturi S.P., Pulendran B. The science of adjuvants. Expert Rev Vaccines 2007, 6(5):673-684.
2. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007, 25(12):1361-1366.
3. Steinman R.M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29(3):319-324.
4. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25-26):3331-3334.
5. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(7):505-517.
6. Raman V.S., Bhatia A., Picone A., Whittle J., Bailor H.R., O'Donnell J., et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 2010, 185(3):1701-1710.
7. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
8. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
9. Cragg G.M., Grothaus P.G., Newman D.J. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009, 109(7):3012-3043.
10. Lam K.S. New aspects of natural products in drug discovery. Trends Microbiol 2007, 15(6):279-289.
11. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70(3):461-477.
12. Billiau A., Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001, 70(6):849-860.
13. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1(2):135-145.
14. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009, 227(1):221-233.
15. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989, 54(Pt 1):1-13.
16. Monie T.P., Bryant C.E., Gay N.J. Activating immunity: lessons from the TLRs and NLRs. Trends Biochem Sci 2009, 34(11):553-561.
17. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004, 16(1):21-25.
18. Franchi L., Warner N., Viani K., Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009, 227(1):106-128.
19. Fritz J.H., Ferrero R.L., Philpott D.J., Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006, 7(12):1250-1257.
20. Fritz J.H., Le Bourhis L., Sellge G., Magalhaes J.G., Fsihi H., Kufer T.A., et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 2007, 26(4):445-459.
21. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
22. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205(4):869-882.
23. Petrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19(6):615-622.
24. McKee A.S., Munks M.W., MacLeod M.K., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183(7):4403-4414.
25. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181(1):17-21.
26. Huysamen C., Brown G.D. The fungal pattern recognition receptor, dectin-1, and the associated cluster of C-type lectin-like receptors. FEMS Microbiol Lett 2009, 290(2):121-128.
27. Robinson M.J., Sancho D., Slack E.C., LeibundGut-Landmann S., Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006, 7(12):1258-1265.
28. Drickamer K. Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 1988, 263(20):9557-9560.
29. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007, 8(6):630-638.
30. Dillon S., Agrawal S., Banerjee K., Letterio J., Denning T.L., Oswald-Richter K., et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006, 116(4):916-928.
31. Takahashi K., Ip W.E., Michelow I.C., Ezekowitz R.A. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol 2006, 18(1):16-23.
32. Elnekave M., Furmanov K., Nudel I., Arizon M., Clausen B.E., Hovav A.H. Directly transfected langerin+dermal dendritic cells potentiate CD8+ T cell responses following intradermal plasmid DNA immunization. J Immunol 2010, 185(6):3463-3471.
33. van de Veerdonk F.L., Marijnissen R.J., Kullberg B.J., Koenen H.J., Cheng S.C., Joosten I., et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009, 5(4):329-340.
34. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315(5808):107-111.
35. Caparros E., Munoz P., Sierra-Filardi E., Serrano-Gomez D., Puig-Kroger A., Rodriguez-Fernandez J.L., et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 2006, 107(10):3950-3958.
36. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 2007, 179(7):4711-4720.
37. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314(5801):997-1001.
38. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327(5963):291-295.
39. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6(10):981-988.
40. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168(9):4531-4537.
41. Tomita T., Kanai T., Fujii T., Nemoto Y., Okamoto R., Tsuchiya K., et al. MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis. J Immunol 2008, 180(8):5291-5299.
42. Gay N.J., Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007, 76:141-165.
43. Bell J.K., Mullen G.E., Leifer C.A., Mazzoni A., Davies D.R., Segal D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003, 24(10):528-533.
44. Schreibelt G., Tel J., Sliepen K.H., Benitez-Ribas D., Figdor C.G., Adema G.J., et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010, 59(10):1573-1582.
45. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 2006, 27(1):49-55.
46. Jankovic D., Kullberg M.C., Hieny S., Caspar P., Collazo C.M., Sher A. In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) setting. Immunity 2002, 16(3):429-439.
47. Pasare C., Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004, 21(5):733-741.
48. Pasare C., Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005, 438(7066):364-368.
49. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2(10):947-950.
50. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
51. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005, 79(5):2910-2919.
52. Berchtold C., Panthel K., Jellbauer S., Kohn B., Roider E., Partilla M., et al. Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium. Infect Immun 2009, 77(12):5501-5508.
53. El-Malky M., Shaohong L., Kumagai T., Yabu Y., Noureldin M.S., Saudy N., et al. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice. Microbiol Immunol 2005, 49(7):639-646.
54. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 2002, 195(12):1565-1573.
55. Kim Y.H., Girardi M., Duvic M., Kuzel T., Link B.K., Pinter-Brown L., et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010, 63(6):975-983.
56. Gupta G.K., Agrawal D.K. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs 2010, 24(4):225-235.
57. Hibino T., Loza-Coll M., Messier C., Majeske A.J., Cohen A.H., Terwilliger D.P., et al. The immune gene repertoire encoded in the purple sea urchin genome. Dev Biol 2006, 300(1):349-365.
58. McDowell J.M., Simon S.A. Molecular diversity at the plant-pathogen interface. Dev Comp Immunol 2008, 32(7):736-744.
59. McDowell J.M., Simon S.A. Recent insights into R gene evolution. Mol Plant Pathol 2006, 7(5):437-448.
60. Chisholm S.T., Coaker G., Day B., Staskawicz B.J. Host-microbe interactions: shaping the evolution of the plant immune response. Cell 2006, 124(4):803-814.
61. Meyers B.C., Kozik A., Griego A., Kuang H., Michelmore R.W. Genome-wide analysis of NBS-LRR-encoding genes in Arabidopsis. Plant Cell 2003, 15(4):809-834.
62. Tan X., Meyers B.C., Kozik A., West M.A., Morgante M., St Clair D.A., et al. Global expression analysis of nucleotide binding site-leucine rich repeat-encoding and related genes in Arabidopsis. BMC Plant Biol 2007, 7:56.
63. Dangl J.L., Jones J.D. Plant pathogens and integrated defence responses to infection. Nature 2001, 411(6839):826-833.
64. Meyerowitz E.M. Plants compared to animals: the broadest comparative study of development. Science 2002, 295(5559):1482-1485.
65. Zelensky A.N., Gready J.E. The C-type lectin-like domain superfamily. FEBS J 2005, 272(24):6179-6217.
66. Zhang H., Wang H., Wang L., Song L., Song X., Zhao J., et al. Cflec-4, a multidomain C-type lectin involved in immune defense of Zhikong scallop Chlamys farreri. Dev Comp Immunol 2009, 33(6):780-788.
67. Schulenburg H., Hoeppner M.P., Weiner J., Bornberg-Bauer E. Specificity of the innate immune system and diversity of C-type lectin domain (CTLD) proteins in the nematode Caenorhabditis elegans. Immunobiology 2008, 213(3-4):237-250.
68. Xu W.T., Wang X.W., Zhang X.W., Zhao X.F., Yu X.Q., Wang J.X. A new C-type lectin (FcLec5) from the Chinese white shrimp Fenneropenaeus chinensis. Amino Acids 2010, 39(5):1227-1239.
69. Huffman D.L., Abrami L., Sasik R., Corbeil J., van der Goot F.G., Aroian R.V. Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins. Proc Natl Acad Sci USA 2004, 101(30):10995-11000.
70. Wiens M., Korzhev M., Perovic-Ottstadt S., Luthringer B., Brandt D., Klein S., et al. Toll-like receptors are part of the innate immune defense system of sponges (demospongiae: Porifera). Mol Biol Evol 2007, 24(3):792-804.
71. Wiens M., Korzhev M., Krasko A., Thakur N.L., Perovic-Ottstadt S., Breter H.J., et al. Innate immune defense of the sponge Suberites domuncula against bacteria involves a MyD88-dependent signaling pathway. Induction of a perforin-like molecule. J Biol Chem 2005, 280(30):27949-27959.
72. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86(6):973-983.
73. Pujol N., Link E.M., Liu L.X., Kurz C.L., Alloing G., Tan M.W., et al. A reverse genetic analysis of components of the Toll signaling pathway in Caenorhabditis elegans. Curr Biol 2001, 11(11):809-821.
74. Gomez-Gomez L. Plant perception systems for pathogen recognition and defence. Mol Immunol 2004, 41(11):1055-1062.
75. Gomez-Gomez L., Boller T. Flagellin perception: a paradigm for innate immunity. Trends Plant Sci 2002, 7(6):251-256.
76. Nurnberger T., Brunner F., Kemmerling B., Piater L. Innate immunity in plants and animals: striking similarities and obvious differences. Immunol Rev 2004, 198:249-266.
77. Narusaka M., Shirasu K., Noutoshi Y., Kubo Y., Shiraishi T., Iwabuchi M., et al. RRS1 and RPS4 provide a dual resistance-gene system against fungal and bacterial pathogens. Plant J 2009, 60(2):218-226.
78. Gassmann W., Hinsch M.E., Staskawicz B.J. The Arabidopsis RPS4 bacterial-resistance gene is a member of the TIR-NBS-LRR family of disease-resistance genes. Plant J 1999, 20(3):265-277.
79. Dai Y., Kato M., Takeda K., Kawamoto Y., Akhand A.A., Hossain K., et al. T-cell-immunity-based inhibitory effects of orally administered herbal medicine juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice. J Invest Dermatol 2001, 117(3):694-701.
80. Dona M., Dell'Aica I., Calabrese F., Benelli R., Morini M., Albini A., et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 2003, 170(8):4335-4341.
81. Meeran S.M., Mantena S.K., Elmets C.A., Katiyar S.K. (-)-Epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interleukin-12-dependent DNA repair. Cancer Res 2006, 66(10):5512-5520.
82. Rivera E., Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010, 12(Suppl. 2):S2.
83. Saville M.W., Lietzau J., Pluda J.M., Feuerstein I., Odom J., Wilson W.H., et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995, 346(8966):26-28.
84. Szajnik M., Szczepanski M.J., Czystowska M., Elishaev E., Mandapathil M., Nowak-Markwitz E., et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28(49):4353-4363.
85. Li X.M., Huang C.K., Zhang T.F., Teper A.A., Srivastava K., Schofield B.H., et al. The Chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma. J Allergy Clin Immunol 2000, 106(4):660-668.
86. Ragupathi G., Damani P., Deng K., Adams M.M., Hang J., George C., et al. Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins. Vaccine 2010, 28(26):4260-4267.
87. Song X., Zang L., Hu S. Amplified immune response by ginsenoside-based nanoparticles (ginsomes). Vaccine 2009, 27(17):2306-2311.
88. Ragupathi G., Yeung K.S., Leung P.C., Lee M., Lau C.B., Vickers A., et al. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 2008, 26(37):4860-4865.
89. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 2007, 104(10):3984-3989.
90. Lindqvist M., Persson J., Thorn K., Harandi A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009, 182(10):6435-6443.
91. Ghosh J., Buckley K.M., Nair S.V., Raftos D.A., Miller C., Majeske A.J., et al. Sp185/333: a novel family of genes and proteins involved in the purple sea urchin immune response. Dev Comp Immunol 2010, 34(3):235-245.
92. Nair S.V., Del Valle H., Gross P.S., Terwilliger D.P., Smith L.C. Macroarray analysis of coelomocyte gene expression in response to LPS in the sea urchin. Identification of unexpected immune diversity in an invertebrate. Physiol Genomics 2005, 22(1):33-47.
93. Akira S. Pathogen recognition by innate immunity and its signaling. Proc Jpn Acad Ser B: Phys Biol Sci 2009, 85(4):143-156.
94. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1):1-13.
95. McArdle B.M., Campitelli M.R., Quinn R.J. A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. J Nat Prod 2006, 69(1):14-17.
96. Feher M., Schmidt J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003, 43(1):218-227.
97. Lipinski C.A., Lombardo F., Dominy B.W., Freeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997, 23:3-25.
98. Quinn R.J., Carroll A.R., Pham N.B., Baron P., Palframan M.E., Suraweera L., et al. Developing a drug-like natural product library. J Nat Prod 2008, 71(3):464-468.
99. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005, 4(3):206-220.
100. Guan Y., Omueti-Ayoade K., Mutha S.K., Hergenrother P.J., Tapping R.I. Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening. J Biol Chem 2010, 285(31):23755-23762.
101. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7(5):353-364.
102. Bugni T.S., Richards B., Bhoite L., Cimbora D., Harper M.K., Ireland C.M. Marine natural product libraries for high-throughput screening and rapid drug discovery. J Nat Prod 2008, 71(6):1095-1098.
103. Koch M.A., Waldmann H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov Today 2005, 10(7):471-483.
104. Vu H., Pham N.B., Quinn R.J. Direct screening of natural product extracts using mass spectrometry. J Biomol Screen 2008, 13(4):265-275.
105. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
106. Hawrylowicz C.M. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005, 202(11):1459-1463.
107. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109(12):1519-1526.
108. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9(14):5091-5100.
109. van den Broek M. Dendritic cells break bonds to tolerize. Immunity 2007, 27(4):544-546.
110. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005, 201(9):1435-1446.
111. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7(8):610-621.
112. Nascimento C.R., Lima M.A., de Andrada Serpa M.J., Espindola O., Leite A.C., Echevarria-Lima J. Monocytes from HTLV-1-infected patients are unable to fully mature into dendritic cells. Blood 2011, 117(2):489-499.
113. Changyong C., Sun M., Li H., Brockmeyer N., Wu N.P. Simian virus 40 inhibits differentiation and maturation of rhesus macaque DC-SIGN(+) dendritic cells. Eur J Med Res 2010, 15(9):377-382.
114. Unger W.W., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009, 39(11):3147-3159.
115. Kong W., Yen J.H., Vassiliou E., Adhikary S., Toscano M.G., Ganea D. Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family. Lipids Health Dis 2010, 9:12.
116. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31(11):3388-3393.
117. Zhan Y., Xu Y., Seah S., Brady J.L., Carrington E.M., Cheers C., et al. Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways. J Immunol 2010, 185(4):2125-2133.
118. Jefford M., Schnurr M., Toy T., Masterman K.A., Shin A., Beecroft T., et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 2003, 102(5):1753-1763.
119. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179(4):1109-1118.
120. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176(6):1693-1702.
121. Brawand P., Fitzpatrick D.R., Greenfield B.W., Brasel K., Maliszewski C.R., De Smedt T. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 2002, 169(12):6711-6719.